STAT+: What’s next for Sarepta Therapeutics with gene therapy under fire?
The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also undermining investor confidence in the company that…
This story is an excerpt from Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The Duchenne muscular dystrophy community is reeling following the second death of a patient from liver failure caused by Sarepta Therapeutics’ gene therapy Elevidys. On Monday, my colleague Jason Mast and I reported on the immediate consequences of this tragic event for Duchenne patients, their caregivers, and physicians.
This newsletter, of course, looks at biotech events through a Wall Street lens, so it’s appropriate to mention here that Sarepta shareholders aren’t feeling all that great, either. What comes next — recovery or more pain — is hard to predict.
